Phase III, double-blind trial of lasofoxifene in postmenopausal with low or normal bone mineral density
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2015
At a glance
- Drugs Lasofoxifene (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacodynamics
- Acronyms OPAL
- 16 Sep 2015 Results will be presented at the North American Menopause Society (NAMS) Annual Meeting 2015, according to a Sermonix Pharmaceuticals media release.
- 05 Nov 2010 New trial record.